Queensland, Australia – Deep Ayurveda India proudly announces the launch of its Ayurvedic Prash and Pure Shilajit Resin in Australia Market. First phase company focused and has appointed exclusive distributors in Queensland, Victoria, New Sourth Wales and soon also going to enter other states. Deep Ayurveda launched spl Shilajit Resin in Australia, Naripanch Shilajit for Women in Australia and Ayurvedic Prash in Australia, Initially Deep Ayurveda shilajit range launching started from Queensland state and with in one month covered all major cities like Brisbane, Gold coast, Sunshine Coast, Toowoomba, Bundaberg, Rockhampton and successfully placed its products in over 100 Indian and Asian grocery stores. Soon, the launch will expand to Victoria, New South Wales, and other states, according to Vishnu Datt Sharma, CEO of Deep Ayurveda.
Deep Ayurveda’s CEO-Mr Vishnu Sharma- highlighted the unique range of Ayurvedic superfoods introduced by the company in India in January 2023. These include Vajayu Prash for men, Naripanch for women, Ashwprash for the elderly, and Kalyankam for children. Within a year, these products gained significant popularity in the men’s wellness category and were widely accepted by Indian consumers. Recently, Deep Ayurveda launched a Pure Shilajit range in India, catering to all ages and genders, including Vajayu Shilajit Gold for men and Naripanch Shilajit for women. Notably, Deep Ayurveda is the first company to launch a Shilajit Resin blend for women based on tridosha balance principles. Mr. Sharma stated that under the expansion plan, the company aims to place its Ayurvedic superfoods and Shilajit resin in 500 retail outlets across Australia by the end of 2024.
Mr. Sharma added that after eight successful years of clinical operations, treating thousands of chronic patients, and another eight years in research and development, Deep Ayurveda decided in December 2022 to expand fully in India through D2C operations and in the Australian market.
Mr. Sharma further stated that Deep Ayurveda entered the Australian market in 2019, but operations were paused due to the COVID-19 pandemic. Operations resumed in June 2023, initially focusing on clinical operations and an online D2C platform. The company has now fully launched its Ayurvedic superfood range & Pure Shilajit Resin in Australia Market , including flagship products Vajayu Prash for men and Naripanch Prash for women, along with the most authentic Shilajit Resin. Deep Ayurveda also plans to apply for TGA GMP certification for its Indian manufacturing facility to promote other therapeutic Ayurvedic products in Australia through pharmacies and health stores.
Australians are increasingly seeking natural therapies as alternatives to chemical-based substitutes:
Dr. Baldeep Kour, Founder and Director of Deep Ayurveda in Australia, emphasized the multicultural nature of Australia and the growing health consciousness among Australians. She noted that Australians are increasingly seeking natural therapies as alternatives to chemical-based substitutes. Dr. Kour also highlighted that Australia is the first country after India to recognize Ayurveda as an alternative medicine, allowing Ayurvedic practitioners to practice legally under the guidelines of TGA and under the code of conduct set by the various association of Alternative Treatment or Natural Medicine Association or the Association of Ayurveda in Australia.
Indian Ayurveda Company Focus to promote most authentic ayurvedic products and Pure Shilajit Resin in Australia Market
Deep Ayurveda aim is focus to promote most authentic ayurvedic products and Pure Shilajit Resin in Australia Market The company has been supplying its Ayurvedic products in Australia and Herbal Products in Australia to selected Ayurvedic practitioners in Australia since 2018. Moving forward, it plans to expand its focus to include Natural Medicine Practitioners, Ayurvedic Practitioners, Naturopaths, and Chinese Herbal Medicine Practitioners, encouraging them to incorporate Deep Ayurveda Superfood and Pure Shilajit Resin into their regular practice.
Dr. Baldeep Kour also shared that from 2007 to 2014, Deep Ayurveda’s primary focus was on clinical operations. During this period, she realized the significant gap in the quality and efficacy of Ayurvedic medicines. This observation led to the company’s decision to enter Ayurvedic product development and research. In October 2014, Deep Ayurveda obtained its manufacturing license from the Ayurveda & Drug Licensing Authority of Punjab State, marking a turning point towards developing efficacy-based and clinically referenced Ayurvedic medicines and supplements. By December 2022, the company had over 250 Ayurvedic medicines and natural products in its portfolio, approved by Ayush/State Drug Licensing Authority in India, with many products also registered in the USA, Europe, Ayurveda in Australia, and UAE.
Indian Ayurveda brand Shilajit Resin in Australia Market
Mr. Sharma also revealed that the company achieved a revenue of $1.25 million in the first year of its D2C operation in 2023-24 (only from Direct to customer operations) with 70% of the revenue generated by Vajayu Prash category only. The company has set an ambitious target of $3.5 million for the current fiscal year 2024-25 through its D2C operations in India, focusing on more unique products this year such as Naripanch Prash, LivBlaya extract-based supplements for liver health, the Shilajit range for men and women, and many more. For the Australian market, the target is set at $1.25 million for FY 2024-25 through its D2C platform Ayurveda in Australia, marketplaces, and retail outlets with Shilajit Resin Category and Ayurvedic Prash range.
Mr. Sharma also stated that the company’s aim is to become the most authentic, trusted, and affordable Ayurvedic brand worldwide, providing a wide range of products for lifestyle enhancement and chronic disease treatment. Deep Ayurveda’s goal is to achieve sales revenue of $60 million by the end of 2027-28 and to launch an IPO. While the company has been bootstrapped so far, they have decided to raise funds to set up a world-class, export-oriented manufacturing unit to enhance production capacity and scale their D2C operations in India and Australia. The company is looking to raise USD $5 million and is on the verge of finalizing a deal with renowned venture capitalists in the consumer, healthcare, and D2C domains.
